Richard G. Everson, MD

Richard G. Everson, MD

Assistant Professor in Residence, Department of Neurosurgery




Neurological Surgery

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica



Neurosurgical Oncology, University of Texas - M.D. Anderson Cancer Center, 2016 - 2017


General Surgery, UCLA School of Medicine, 2009 - 2010


MD, Duke University School of Medicine, 2009


Neurosurgery, UCLA School of Medicine, 2010 - 2016

Board Certification

Neurological Surgery, American Board of Neurological Surgery, 2021

Contact Information

Clinical Interests

Acoustic Neuromas, Anaplastic Astrocytoma (Grade III Glioma), Artificial Disc, Astrocytoma (Grade II Gliomas), Brain Injury, Brain Stem Tumors, Brain Tumor, Cavernous Malformation (aka Cavernoma), Chondrosarcomas, Chordomas, CNS Lymphoma, Craniopharyngiomas, Cushing's Disease, Dermoid Cysts, Encephalocele, Endoscopic Endonasal Surgery, Endoscopic Surgery, Endoscopic Third Ventriculostomy, Ependymoma, Epidermoid Cyst, Epidermoid Tumors, Epilepsy Surgery, Facial/Hemifacial Spasms, Gangliomas, General Neurosurgery, Gliobastoma (Grade IV Glioma), Glommus Jugulare Tumors, Head Trauma, Hydrocephalus, Intracerebral Hemorrhage, Kyphoplasty, Lipoma, Medulloblastomas, Meningiomas, Nerve Tumor, Neuro Endoscopy, Neuro Physiology, Oligodendroglioma, Oncology, Optic Nerve Gliomas, Petrous Apex Cholesterol Granuloma, Pilocytic Astrocytoma (Grade I Glioma), Pineal Tumor/Cyst, Pituitary Tumors, Rathke Cleft Cysts, Seizure Disorder, Skull Base Tumors, Spinal Cord Tumors, Spine, Spine Minimally Invasive, Spine Surgery, Spine Surgery Instrumentation, Stereotactic Biopsy, Stereotactic Radiosurgery, Syringomyelia, Vascular Tumors, Vestibular Schwannoma

Scientific Interests

Dr. Richard Everson's research is focused on:

  • Clinical trials for patients with central nervous system tumors
  • Evaluating the makeup of individual patient tumors including next generation sequencing to identify targetable mutations (by both targeted therapies and immunotherapy) establishing treatment models (cell lines, avatars) and using flow cytometry and cytoff to understand the immune cell populations within a tumor
  • Developing next-generation immunotherapy treatments included engineered T-cell therapies for cancers in the central nervous system
  • Understanding the causes of, and determining treatments for, tumor genetic syndromes such as neurofibromatosis and schwannomatosis

Highlighted Publications

Al-Holou WN, Hodges TR, Everson RG, Freeman J, Zhou S, Suki D, Rao G, Ferguson SD, Heimberger AB, McCutcheon IE, Prabhu SS, Lang FF, Weinberg JS, Wildrick DM, Sawaya R. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2019 Feb 25. pii: nyz008. doi: 10.1093/neuros/nyz008. [Epub ahead of print]

Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro Oncol. 2019 May 4. pii: noz078. doi: 10.1093/neuonc/noz078. [Epub ahead of print]

Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep;139(2):469-478. doi: 10.1007/s11060-018-2891-8. Epub 2018 May 30.

Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.

Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10220-10225. doi: 10.1073/pnas.1706689114. Epub 2017 Sep 5.